KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $4.4 billion.

  • Gsk's Cash & Equivalents rose 721.17% to $4.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year increase of 721.17%. This contributed to the annual value of $4.9 billion for FY2024, which is 3546.3% up from last year.
  • According to the latest figures from Q3 2025, Gsk's Cash & Equivalents is $4.4 billion, which was up 721.17% from $4.8 billion recorded in Q2 2025.
  • Gsk's Cash & Equivalents' 5-year high stood at $14.7 billion during Q1 2022, with a 5-year trough of $3.5 billion in Q1 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $4.4 billion (2025), whereas its average is $5.3 billion.
  • Per our database at Business Quant, Gsk's Cash & Equivalents surged by 12434.41% in 2022 and then tumbled by 7612.91% in 2023.
  • Over the past 5 years, Gsk's Cash & Equivalents (Quarter) stood at $5.8 billion in 2021, then decreased by 24.21% to $4.4 billion in 2022, then fell by 16.55% to $3.6 billion in 2023, then soared by 36.31% to $5.0 billion in 2024, then dropped by 10.48% to $4.4 billion in 2025.
  • Its Cash & Equivalents stands at $4.4 billion for Q3 2025, versus $4.8 billion for Q2 2025 and $5.6 billion for Q1 2025.